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Abstract
Nicotinic acetylcholine receptors (nAChRs) are involved in seizure mechanisms. Hence, nocturnal frontal lobe epilepsy was
the first idiopathic epilepsy linked with specific mutations in a4 or b2 nAChR subunit genes. These mutations confer gain of
function to nAChRs by increasing sensitivity toward acetylcholine. Consistently, nicotine elicits seizures through nAChRs and
mimics the excessive nAChR activation observed in animal models of the disease. Treatments aimed at reducing nicotinic
inputs are sought as therapies for epilepsies where these receptors contribute to neuronal excitation and synchronization.
Previous studies demonstrated that peroxisome proliferator-activated receptors-a (PPARa), nuclear receptor transcription
factors, suppress nicotine-induced behavioral and electrophysiological effects by modulating nAChRs containing b2
subunits. On these bases, we tested whether PPARa agonists were protective against nicotine-induced seizures. To this aim
we utilized behavioral and electroencephalographic (EEG) experiments in C57BL/J6 mice and in vitro patch clamp
recordings from mice and rats. Convulsive doses of nicotine evoked severe seizures and bursts of spike-waves discharges in
,100% of mice. A single dose of the synthetic PPARa agonist WY14643 (WY, 80 mg/kg, i.p.) or chronic administration of
fenofibrate, clinically available for lipid metabolism disorders, in the diet (0.2%) for 14 days significantly reduced or
abolished behavioral and EEG expressions of nicotine-induced seizures. Acute WY effects were reverted by the PPARa
antagonist MK886 (3 mg/kg, i.p.). Since neocortical networks are crucial in the generation of ictal activity and synchrony, we
performed patch clamp recordings of spontaneous inhibitory postsynaptic currents (sIPSCs) from frontal cortex layer II/III
pyramidal neurons. We found that both acute and chronic treatment with PPARa agonists abolished nicotine-induced sIPSC
increases. PPARa within the CNS are key regulators of neuronal activity through modulation of nAChRs. These effects might
be therapeutically exploited for idiopathic or genetically determined forms of epilepsy where nAChRs play a major role.
Citation: Puligheddu M, Pillolla G, Melis M, Lecca S, Marrosu F, et al. (2013) PPAR-Alpha Agonists as Novel Antiepileptic Drugs: Preclinical Findings. PLoS ONE 8(5):
e64541. doi:10.1371/journal.pone.0064541
Editor: Ste´phane Charpier, University Paris 6, France
Received January 9, 2013; Accepted April 15, 2013; Published May 27, 2013
Copyright:  2013 Puligheddu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by the Italian Ministry of University (MIUR) to Marco Pistis (grant PRIN 2009: 200928EEX4) and to Francesco Marrosu and
Anna Lisa Muntoni (grant PRIN 2009: 2009HST9YF) by the FIRE-AICE 2011 grant and Fondazione Banco di Sardegna grant 2012 to Marco Pistis. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mpistis@unica.it
. These authors contributed equally to this work.
Introduction
Binding of nicotine to nicotinic acetylcholine receptors
(nAChRs) elicits in laboratory animals dose-dependent effects that
begin with hypermotility and culminate with clonic-tonic seizures
and death at high doses [1]. Investigation on the mechanisms
underlying nicotine-induced seizures might help to understand
how nAChRs participate in the mechanisms of epilepsy. Interest
for nAChR in several epileptic syndromes previously considered
‘‘idiopathic’’ was rekindled by the finding that altered functional
properties of nAChR are implicated in the pathogenesis of
nocturnal frontal lobe epilepsy (NFLE), and that seizures induced
by nicotine in rodents model nAChR-related epilepsy. NFLE is
linked with mutations of the a4 or b2 subunits [2,3,4,5,6,7], the
most abundantly expressed subunits in the CNS [8]. Though in
human NFLE, or in genetically engineered mice that model the
disease, functional properties of nAChRs are intimately altered,
nicotine evokes seizures by over-activating a healthy system.
However, several neurophysiological events ultimately leading to
seizures may share common steps between these conditions.
Indeed, the common trait in enhancing the epileptogenesis is the
over-activation of cholinergic systems, either pharmacologically
induced or mediated by the gain of function that mutated nAChRs
exhibit toward their ligands [9]. These effects might be based on
the extensive expression of nAChRs, particularly those containing
the b2 subunit (b2*nAChRs) in thalamo-cortical, hippocampal
and frontal regions [10]. Indeed, altered cholinergic activation of
neocortical and/or thalamocortical networks plays a central role in
the generation of both nicotine-induced and NFLE seizures, which
originate in the frontal cortex (FCx) [11] and specifically affect
GABAA-mediated inhibitory inputs to pyramidal neurons [12].
Based on this evidence, negative regulation of nAChRs might
represent a potential therapeutic approach in nAChR-related
forms of epilepsies.
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We previously discovered that nicotine-evoked excitation of
dopamine neurons both in vivo and in vitro, as well as nicotine
addictive properties in rats and monkeys, are suppressed by ligands
to the peroxisome-proliferator-activated receptor-a (PPARa)
[13,14,15,16]. PPARa is one of three subtypes of the nuclear
receptor PPAR family [17,18,19], expressed by neurons in many
brain regions [20,21], and activated by endogenous ligands, the N-
acylethanolamines oleoylethanolamide (OEA) and palmitoyletha-
nolamide (PEA) [22], and by synthetic ligands such as hypolip-
idemic fibrates [16].
Evidence points to a non-transcriptional interaction between
PPARa and nAChR, via phosphorylation [13,14,23]. This
mechanism might account for the blockade of neuronal and
behavioral responses to nicotine [13,15,16].
Building upon these findings, we postulated that PPARa
agonists might display anticonvulsant properties. Thus, we first
investigated whether acutely or chronically administered PPARa
ligands reduce the severity of nicotine-induced seizures. Next, we
assessed whether these compounds regulate the phosphorylation
status of the b subunit of the nAChR and abolish nicotine-induced
enhancement of inhibitory currents on pyramidal neurons in
layers II/III of the frontal cortex (FCx) in mice and rats.
Materials and Methods
Animals
For behavioral experiments, electroencephalographic (EEG)
and patch-clamp recordings male C57BL/6J mice (Harlan, San
Pietro al Natisone, Italy) (n=80; weight: 25–30 g each) were used.
For immuno-blotting experiments and patch-clamp recordings, we
utilized male Sprague-Dawley rats (250–300 g and 14–21 d,
respectively, n = 30, Harlan, San Pietro al Natisone, Italy) Mice
and rats were housed six per cage under a 12 h light/dark cycle
(light on at 7:00 AM), in conditions of constant temperature
(2162uC) and humidity (60%), with food and water ad libitum.
Ethics Statement
Experiments were performed in strict accordance with the EEC
Council Directive of 24 November 1986 (86/609). All efforts were
made to minimize pain and suffering and to reduce the number of
animals used. The experimental protocols were also approved by
the Animal Ethics Committee of the University of Cagliari.
Treatments
Animals were randomly assigned to the experimental groups
undergoing behavioral seizure scoring or EEG recordings. In the
first set of experiments a dose-response curve for nicotine (5, 7,
10 mg/kg) was carried out. Each mouse received a single dose of
nicotine.
Subsequent acute experiments, aimed to assess the effect of the
PPARa agonist WY14643 or the antagonist MK886, were carried
out with the 10 mg/kg dose of nicotine. In these cases, mice
received two injections, spaced by 10 min intervals, before the
final nicotine administration after 15 min: we first injected the
antagonist MK886 (3.0 mg/kg, i.p.) or its vehicle followed by the
administration of WY14643 (80 mg/kg, i.p.) or its vehicle.
For chronic studies, one week after EEG electrode implants (see
below) mice were divided into diet treatment groups: (i) a standard
diet (control group, Harlan Teklad Global 2016); (ii) a 0.2%
fenofibrate diet (Fenofibrate from Sigma-Aldrich+Harlan Teklad
Global 2016). Mice were fed diets for 14 days. On the day of the
experiment, mice received one injection [MK886 (3.0 mg/kg,
i.p.)] or its vehicle before nicotine (10 mg/kg) administration after
15 min.
Seizure Scoring
Immediately after nicotine injection, mice were placed in a
regular mouse cage with bedding, and behavioral responses were
recorded for 5 min. The symptoms were scored independently by
two experimenters blind to the treatment on an arbitrary scale
from 0 to 6 (modified from Franceschini et al., 2002) [24] as
follows: 0, no visible effects; 1, locomotor effects including
increased exploring activity and/or sedation; 2, tachypnea,
tremors, back arching; 3, any combination of the symptoms in 1
and 2 plus rapid movements of the legs, wild running, or partial
loss of righting reflex; 4, any combination of the previous
symptoms plus complete loss of righting reflex, clonic seizures, 5,
any combination of the preceding symptoms plus tonic seizures; 6,
death, with or without hyperextension of the limbs along the axis
of the body (soldier position).
EEG Recordings
Mice were anesthetized with Equithesin (5 ml/kg, i.p.) and
placed in a stereotaxic apparatus (David Kopf, mod. 900). The
skull was exposed and perforated, the holes aimed at the following
positions: one located above the (either left or right) sensorimotor
cortices (FPr and FPl), [coordinates from bregma (mm): antero-
posterior +2, lateral 3, ventral to skull surface 1.5], two targeted to
the dorsal hippocampus with bipolar leads glued together
[coordinates from bregma (mm): anteroposterior +2, lateral 1
and 2, ventral 1.3 and 2] and one on the skull over the cerebellum
as a reference [coordinates from bregma (mm): anteroposterior
25.9, lateral 1.5] [25]. A four-pin male socket was positioned into
the holes, secured to the skull with epoxy resin and covered with
acrylic cement to improve retention.
One week following surgical preparation of the animals (or three
to five weeks for chronic studies), experiments started according to
the protocol described above, electrical potentials were acquired
and the signals amplified, bandpass-filtered and recorded on a
portable digital EEG polygraph (BQS 98 System Micromed). In
addition, in view of the possibility that digital data generated by
the above mentioned experimental settings may need unconven-
tional processing, further home-made software analysis rewritten
on a MatlabH platform was used (e.g. signal analysis with wavelets
versus traditional fast Fourier transform (FFT) processing).
Electrode impedance was maintained at ,5 kV. The amplified
signals, processed with a band-pass filter (0.02 to 70 Hz), was
stored on the hard disk at a sampling rate of 256/s.
The behavior of the animals was video-recorded for the entire
duration of the experiment.
In vitro Electrophysiology
The preparation of FCx slices and whole-cell patch clamp
recordings from layer II/III pyramidal neurons was as described
previously [12]. Briefly, male mice (10–25 d, Harlan) and Sprague
Dawley rats (14–21 d, Harlan) were anesthetized with halothane
and killed. A block of tissue containing the FCx was sliced in the
coronal plane (300 mm) with a vibratome (Leica, Nussloch,
Germany) in ice-cold low Ca2+ artificial cerebrospinal fluid
(ACSF) containing (in mM): 126 NaCl, 2.5 KCl, 2 CaCl2,
2 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose
(pH 7.3–7.4). Slices (two per animal) were transferred in a holding
chamber and allowed to recover for at least 1 hr before being
placed in the recording chamber and superfused with ACSF (32–
34uC) saturated with 95%O2/5%CO2:
FCx layer II/III pyramidal cells were identified visually with an
upright microscope with infrared illumination, and whole-cell
voltage-clamp recordings were made by using an Axopatch 200B
amplifier (Molecular Devices, CA). All GABAA IPSC recordings
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were made with electrodes filled with an internal solution
containing the following (mM): 140 cesium-methylsulfonate, 0.2
EGTA, 5 NaCl, 10 HEPES, 2 Mg2ATP, 0.25 Mg2GTP, pH 7.2–
7.4. Experiments were begun only after series resistance had
stabilized (typically 15–40 MV). Series resistance and input
resistance were monitored continuously on-line with a 4 mV
depolarizing step (25 ms). Data were filtered at 2 KHz, digitized at
10 KHz, and collected on-line with acquisition software (Clampex
8.2, Molecular Devices, CA). Neurons were voltage-clamped at a
membrane potential of 0 mV. All GABAA spontaneous IPSCs
were recorded in presence of 2-amino-5-phosphonopentanoic acid
(AP5; 100 mM), 6-cyano-2,3-dihydroxy-7-nitro-quinoxaline
(CNQX; 10 mM), to block N-methyl-D-aspartate- (NMDA), a-
amino-3-hydroxy-5-methyl-isoxazolepropionic acid- (AMPA) me-
diated synaptic currents, respectively. As already described [12],
there was no effect of this solution on the holding current of the
pyramidal cells.
N-acylethanolamine Quantification
Male C57BL/6J mice (Harlan, San Pietro al Natisone, Italy)
were fed, as described above, with a standard diet or a 0.2%
fenofibrate diet. After 14 days, mice were killed and brain rapidly
removed. Frontal cortex slices were obtained and immediately
frozen. Frozen slices were homogenized and extracted with
chloroform/methanol/Tris-HCl 50 mM pH 7.5 (2:1:1, v/v)
containing internal deuterated standards for PEA and OEA
quantification by isotope dilution ([2H]4 PEA, [2H]4 OEA;
Cayman Chemicals, MI, USA). The lipid-containing organic
phase was dried down, weighed and pre-purified by open bed
chromatography on silica gel. Fractions were obtained by eluting
the column with 90:10 (v/v) chloroform/methanol. PEA and OEA
were quantified by liquid chromatography-atmospheric pressure
chemical ionization-mass spectrometry (LC-APCI-MS) [(Agilent
1100 HPLC system (Agilent, Palo Alto, CA, USA) equipped with
MS Detector 6110 single quadruple)], and using selected ion
monitoring at M +1 values for the four compounds and their
deuterated homologues, as previously described [26,27].
Phosphorylation of nAChRs
Phosphorylation of the b2*-nAChRs by the PPARa agonist was
assessed ex vivo by immunoblotting in rat brain homogenates. Rats
(250–300 g) were treated with the PPARa agonist WY14643
(40 mg/kg, i.p.) or vehicle and killed after 15 min. Brains were
rapidly removed and the FCx was immediately frozen in liquid
nitrogen. The tissue was then sonicated in cell lysis buffer (50 mM
TRIS, pH 7.4, 250 mM NaCl, 5 mM EDTA, 50 mM NaF,
1 mM sodium orthovanadate, 1% Triton X-100, 0.02% NaN3)
containing1 mM phenylmethylsulfonyl fluoride and protease
inhibitor cocktail. Protein concentrations of the lysates were
measured by the Bio-Rad Dc Protein Assay.
b2 subunit protein was immunoprecipitated from whole-cell
lysates using a rabbit polyclonal antibody raised against a
recombinant protein corresponding to amino acids 342–433 of
the human b2 subunit (sc-11372, Santa Cruz Biotechnology).
Antibodies were coupled to protein A Dynabeads (Invitrogen)
using 5 mg anti-b2 antibody by rotating the mixture for 10 min at
room temperature. Beads were washed twice in PBS and then the
antibody-conjugated beads were incubated with 500 mg of protein
lysate for 10 min at 4uC, followed by 3 washing steps in PBS
supplemented with 0.1% Tween 20 (Sigma-Aldrich). Bound
protein was eluted with 46 XT Sample buffer (Bio-Rad) and
Reducing agent (Bio-Rad).
The immuno-precipitates were separated on an XT Criterion
10% gel (Bio-Rad, Copenhagen, Denmark) with 16XT MOPS
running buffer (Bio-Rad) for 1 hour at 175 V (constant) and
subsequently electro-transferred to a nitrocellulose membrane at
400 mA (constant) for 1 hour. The membranes were incubated
with 4G10 anti-phosphotyrosine (PY) antibodies (Upstate Biotech-
nology).
Chemiluminescence was detected and quantified with the
Versa Doc 1000 Imaging System (Bio- Rad Laboratories,
Hercules, CA, USA). Samples from control and treated rats
were run on the same immunoblots and then analyzed together.
Values obtained from treated rats were calculated as percentage
of control values.
Drugs
Nicotine [(2)-nicotine hydrogen tartrate)] and fenofibrate were
purchased from Sigma (Italy). Nicotine was dissolved in 0.9%
NaCl solution and the pH was adjusted to 7.0 with 0.1 M NaOH.
Concentrations were adjusted for the mouse to receive 10 ml/g of
nicotine solution. WY14643 and MK886 were purchased from
Tocris. WY14643 and MK886 were dissolved in a solution
containing 10% Tween80, 20% dimethyl sulfoxide (DMSO) and
70% distilled water. All drugs for patch-clamp experiments were
dissolved in DMSO as stock solutions and then diluted to the final
volume in ACSF (final concentration ,0.01%).
Statistical Analysis
Seizure scores (expressed as mean 695% confidence interval,
C.I.) were analyzed by utilizing Kruskal-Wallis test for non-
parametric data, and Dunn’s test as a post-hoc.
Electrophysiological experiments were sampled on line and off
line with data analysis electrophysiology software by computers
connected to specific interface. Drug-induced changes in sIPSCs
were calculated by averaging the effects following drug adminis-
tration and normalized to the pre-drug baseline.
Data were analyzed utilizing parametric one-way ANOVA or
Student’s t-test, when they had equal variance and were normally
distributed; nonparametric t-test was utilized in all other
circumstances. Post hoc multiple comparisons were made using
the Dunnett’s or Newman-Keuls’test when appropriate. Western
blot data were analyzed using Student’s t-test. Contingency tables
were analyzed using Fisher’s exact test. Alpha was set at P,0.05.
All analyses were performed using the software Statistica 6
(StatSoft inc. Tulsa, OK, USA).
Results
Measurement of Nicotine-induced Seizures
Nicotine was subcutaneously administered at the doses of 5
(n = 4), 7 (n = 5), and 10 mg/kg (n= 18) in mice and its effects
were observed during 5 min after injection by two observers
blind to the treatment. Data for behavioral observations were
also obtained from mice carrying electrodes for EEG recordings,
and were pooled with those obtained from non-implanted
animals.
After a first exploratory phase, mice displayed impaired
locomotor activity with shakes. A few seconds later they developed
strong tachypnea with tremors, back arching, and partial loss of
righting reflex. At higher doses, the previous symptoms were
followed by increased locomotor activity, with rapid movements of
the legs and wild running. Clonic and tonic seizures occurred after
complete loss of righting reflex. Fig. 1A shows that nicotine elicited
seizures with dose-dependent severity (r2 = 0.76, P,0.001). The
calculated ED50 for nicotine was 5.0860.07 mg/kg, similar to that
already reported in the literature for the same mouse strain [24].
Only the dose of 10 mg/kg was able to induce severe symptoms,
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which scored higher than 3. In this case, the number of animals
which scored 4 or 5 was 15 out of 18 (83%) and, therefore, we
chose this dose for the subsequent experiments.
The PPARa agonist WY14643 Acutely Reduces the
Severity of Nicotine-induced Seizures
To test the effect of the PPARa agonist WY14643 (WY, 80 mg/
kg, i.p.) and the antagonist MK886 (MK, 3 mg/kg, i.p.) on
nicotine-induced seizures, mice were randomly assigned to three
groups: i) the vehicle-vehicle-nicotine (VEH group), ii) the vehicle-
WY-nicotine group (WY group), and iii) the MK886-WY-nicotine
group (MK-WY group). Each animal received the three injections
spaced 10 and 15 min (Fig. 1B).
When scores were evaluated, non-parametric ANOVA yielded
a highly significant difference among groups (P,0.0001, Kruskal-
Wallis test) (Fig. 1C). Post-hoc analysis revealed that mice pre-
treated with the PPARa agonist WY14643 were significantly
protected against nicotine-induced seizures when compared with
vehicle pre-treated animals. The difference in the average score
was statistically significant (VEH mice: 3.860.4, n= 18; WY mice:
2.960.5, n= 24; P= 0.019, Dunn’s test) (Fig. 1C). Additionally,
WY mice which obtained a score of 4 or 5 were 46% of all treated
mice (11 out of 24). The difference was statistically significant
when compared with the VEH-group (15/18, 83%) (P,0.05,
Fisher’s test, Fig. 1D). The protective effect of WY was reverted by
the PPARa antagonist MK. Hence, post-hoc analysis indicated
that in the MK-WY-group the severity of nicotine-induced
seizures was restored, since the average score was significantly
higher than that assigned to the WY mice (4.460.5, n= 16,
P= 0.001, Dunn’s test, Fig. 1C), but not different from that of
VEH-mice (P.0.05, Dunn’s test) (Fig. 1C). Consistently, MK-WY
mice receiving a score of 4 or 5 were 15 out of 16 (94%) (P= 0.6 vs.
VEH mice) (Fig. 1D).
In vivo electrophysiological recordings revealed that high doses of
nicotine elicited seizures that originate in the hippocampus [28]
and in the thalamo-cortical pathways [11]. These neural circuits
may also be involved in NFLE (for review, see [29]). For this
reason, one EEG electrode was placed in the sensorimotor cortex
and two in the dorsal hippocampus. Of the two electrodes
positioned in the hippocampus the one with the best signal was
chosen.
As depicted in Fig. 2, nicotine-induced (10 mg/kg, s.c.)
convulsive activity was paralleled by a synchronous spiking
discharge pattern both in the hippocampus and in the cortex in
7 out of 7 (100%) treated mice (Fig. 2A, B). Spiking activity had an
onset of 13067 s after nicotine injection and a duration of
52610 s (n = 7). No spike/wave discharge events were recorded in
vehicle treated mice (Fig. 2 A, B).
Pretreatment with WY significantly attenuated the effects of
nicotine, since only 3 out of 9 (33.3%) mice displayed spiking
activity when compared with vehicle-treated mice (P,0.05,
Fisher’s test, Fig. 2B). WY pretreatment, however, did not
change either the onset or the duration of spike-wave activity in
those animals not responding to the treatment (114666 s and
Figure 1. The PPARa agonist WY14643 reduces nicotine-
induced seizures. (A) Graph displaying the dose-dependency of the
severity of nicotine-induced seizures in C57BL/6 mice. Nicotine was
administered subcutaneously at 5, 7 and 10 mg/kg (n = 4, n = 5, n = 18,
respectively). (B) Schematic representation of the experimental protocol
of experiments in (C) and (D). (C) The PPARa agonist WY14643 (WY,
80 mg/kg, i.p., n = 23) reduced the severity of nicotine-induced seizures
(nicotine dose: 10 mg/kg, s.c) (*P,0.05 vs. vehicle, Dunn’s-test). This
effect was abolished by the selective PPARa antagonist MK886 (MK,
3 mg/kg, i.p.). (n = 16, # P,0.001 vs. WY, Dunn’s-test). (D) This graph
shows that the percentage of mice undergoing severe nicotine-induced
seizures (indexed by scores .3) is significantly attenuated after
WY14643 pretreatment (*P,0.05 vs. vehicle, Fisher’s test). MK886
reversed this effect (P.0.05 vs. vehicle, Fisher’s test). Data are expressed
as mean695% C.I.
doi:10.1371/journal.pone.0064541.g001
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32618 s, respectively, n = 3). Consistent with behavioral exper-
iments, MK prevented WY-induced protection from seizures,
since nicotine’s effect was restored in 7 out of 9 mice (77.8%)
(Fig. 2A, B).
Chronic Administration of the Clinically Available PPARa
agonist Fenofibrate Attenuates the Severity of Nicotine-
induced Seizures
The results of the previous experiments prompted us to assess
the efficacy of the clinically available PPARa agonist fenofibrate.
Fenofibrate does not cross the blood-brain barrier rapidly enough
to allow acute studies in vivo; therefore, we chronically treated the
animals with a diet containing 0.2% w/w fenofibrate [30]. Mice
were randomly divided into three groups: (i) fenofibrate diet (FBR),
(ii) control diet (CTRL) and (iii) fenofibrate washout diet (FBR-
WO). The fenofibrate containing diet was administered ad libitum
for 14 days. FBR mice consumed a daily average of 3.660.1 g of
food pellets, which approximately corresponds to 28–30 mg/kg
fenofibrate per day. FBR mice were divided in two additional
groups at the end of the treatment: one group received the PPARa
antagonist MK886 15 min before the nicotine challenge, and the
other received its vehicle. CTRL mice were fed with the control
diet, identical and equicaloric but without fenofibrate. FBR-WO
mice were fed for 14 days with a fenofibrate-containing diet, as
FBR mice, and then fed with a control diet for additional 14 days
to assess the effect of fenofibrate washout. In each animal EEG
electrodes were implanted 7 days before the beginning of the
treatments and nicotine was tested on the 15th day from the
beginning of treatment (for FBR and CTRL mice) or on the 30th
day (for FBR-WO mice).
When nicotine-induced seizures were scored, non-parametric
ANOVA yielded a highly significant difference among groups
(P,0.0001, Kruskal-Wallis test) (Fig. 3A). Post-hoc analysis
revealed that FBR mice were significantly protected against
nicotine-induced seizures when compared with CTRL animals.
The difference in the average score was statistically significant
(CTRL mice: 3.460.7, n= 14; FBR mice: 2.160.3, n= 8;
P,0.001, Dunn’s test) (Fig. 3A). Additionally, none among the
FBR mice obtained a score of 4 or 5 (0 out of 8) (Fig. 3 B). The
difference was statistically significant when compared with the
CTRL group (11/14, 78%) (P,0.001, Fisher’s test, Fig. 3B). The
protective effect of the fenofibrate diet was not reverted by the
PPARa antagonist MK. Hence, post-hoc analysis indicated that in
the MK-treated FBR mice the severity of nicotine-induced
seizures was not restored, since the average score was significantly
lower than that assigned to CTRL mice (2.460.4, n = 8, P,0.001,
Dunn’s test, Fig. 3A), but not different from that of FBR-mice
(P.0.05, Dunn’s test) (Fig. 3A). Consistently, no MK-treated FBR
mice received a score of 4 or 5 (Fig. 3B).
The lack of effect by MK could be explained by the fact that
PPARa activation induces mitochondrial activity, peroxisomal b-
oxidation and the biosynthesis of endogenous PPARa ligands, the
N-acylethanolamines OEA and PEA. These combined effects
might trigger a feed-forward mechanism to further sustain PPARa
activity [31]. To test this hypothesis we measured the levels of
OEA and PEA in the FCx from FBR and CTRL mice. As
predicted, in FBR mice OEA levels were significantly increased in
the FCx when compared to CTRL mice (729.5673.4 pm/g vs.
484.3638.4 pm/g; n= 5; P,0.05, Student’s t-test) (Fig. 3C). No
changes of PEA levels were detected (FBR: 221.7623.0 pm/g;
CTRL: 245.6618.4 pm/g; n= 5; P= 0.44 Student’s t-test)
(Fig. 3C).
Fenofibrate washout for 14 days abolished the protective effects
of the drug, since in FBR-WO mice the severity of nicotine-
induced seizures was restored (Fig. 3A). FBR-WO mice received a
score of 3.560.6 (n = 8), significantly higher that FBR mice
(P,0.05, Dunn’s test) but not dissimilar from CTRL mice
(P.0.05, Dunn’s test) (Fig. 3A).
Figure 2. The PPARa agonist WY14643 suppresses nicotine-
induced spike-wave activity. (A) Representative traces of EEG
recordings from hippocampal (Hip) and sensorimotor cortical (Ctx)
electrodes chronically implanted in mice. Following the administration
of vehicle (VEH) and 10 mg/kg nicotine, bursts of synchronous spike-
wave (SW) activity with high-amplitude and low-frequency (most in the
delta rhythm range) were recorded. This activity was suppressed when
animals were pretreated with the PPARa agonist WY14643 (WY, 80 mg/
kg), which per se did not change baseline EEG activity. The PPARa
antagonist MK886 (MK, 3 mg/kg, i.p.) restored nicotine-induced SW
discharges. (B) The graph shows the percentage of mice presenting SW
discharges following the three treatment protocols. Vehicles treated
mice did show SW activity, whereas 100% of nicotine treated mice
displayed bursts of SW activity. The effects of nicotine were blocked in
the majority of WY treated mice, since SW burst were recorded only in
33% of treated animals (**P,0.01 vs. vehicle, Fisher’s test). Conversely,
when MK was administered 15 before WY nicotine-induced SW activity
was recorded in 78% of MK+WY treated mice (#P,0.05 vs. WY, Fisher’s
test).
doi:10.1371/journal.pone.0064541.g002
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EEG recordings revealed that nicotine-induced (10 mg/kg, s.c.)
convulsive activity was paralleled by a synchronous spiking
discharge pattern in both the hippocampus and the cortex in 6
out of 7 (86%) CTRL mice (Fig. 3D, E). Spiking activity had an
onset of 14868 s after nicotine injection and a duration of 5369 s
(n = 6).
The effect of nicotine was significantly attenuated in FBR mice,
since only 2 out of 8 (25%) mice displayed spiking activity, when
compared with CTRL mice (P,0.05, Fisher’s test, Fig. 3E). In
FBR mice, however, neither the onset nor the duration of spike-
wave activity changed in those animals not responding to the
treatment (179.5625 s and 2762 s, respectively, n = 2).
The effects of nicotine were restored in FBR-WO mice: spiking
activity was indeed present in 5 out of 8 mice (P.0.05 vs. CTRL
mice, Fisher’s test) (Fig. 3E). Consistent with behavioral exper-
iments, MK did not block FBR-induced protection from seizures,
since nicotine’s spike-wave activity was assessed in 2 out of 8 mice
(25%) (Fig. 3E).
Figure 3. The clinically used PPARa agonist fenofibrate chronically administered with food reduces nicotine-induced seizures and
spike-wave activity, and increases the OEA levels in the frontal cortex. (A) Graph displaying that fenofibrate (n = 8, FBR, 0.3% w/w in the
diet for 14 days) reduced the severity of nicotine-induced seizures (nicotine dose: 10 mg/kg, s.c) (***P,0.001 vs. control diet, CTRL DIET, Dunn’s-test).
This effect was not abolished by the selective PPARa antagonist MK886 (FBR+MK, 3 mg/kg, i.p.) (n = 8, **P,0.01 vs. CTRL DIET, Dunn’s-test) but by
withdrawal of fenofibrate treatment for 14 days (FBR WASH-OUT, n = 8, # P,0.05 vs. FBR and P.0.05 vs. CTRL DIET, Dunn’s test). (B) This graph
shows that the percentage of mice undergoing severe nicotine-induced seizures (indexed by scores .3) is significantly attenuated after chronic
fenofibrate treatment (***P,0.001 vs. control diet, Fisher’s test) and restored after fenofibrate withdrawal for 14 days (#P.0.05 vs. control diet).
MK886 did not reverse this effect (***P,0.001 vs. control diet, Fisher’s test). (C) Chronic activation of PPARa by fenofibrate changes
oleoylethanolamide (OEA), but not palmitoylethanolamide, levels within frontal cortex. Concentrations of these endogenous PPARa ligands are
expresses as pmol per gram of tissue. Error bars depict S.E.M. (*P,0.05, Student’s t-test). (D) Representative traces of EEG recordings from
hippocampal (Hip) and sensorimotor cortical (Ctx) electrodes chronically implanted in mice. In mice fed with control diet 10 mg/kg nicotine elicits
bursts of synchronous spike-wave (SW) activity with high-amplitude and low-frequency (most in the delta rhythm range). This activity was suppressed
in animals fed with fenofibrate in food pellets. (E) The graph shows the percentage of mice presenting SW discharges following the four treatment
protocols. 86% of control diet fed mice (6 out of 7) did show nicotine-induced SW activity. The effects of nicotine were fully blocked in all fenofibrate
treated mice, since SW burst were recorded only in none of treated animals (***P,0.01 vs. control diet, Fisher’s test). MK, administered 15 before
nicotine, did not restore nicotine-induced SW activity (***P,0.001 vs. control diet, Fisher’s test), whereas fenofibrate washout did (#P.0.05 vs.
control diet, Fisher’s test). Data are expressed as mean695% C.I.
doi:10.1371/journal.pone.0064541.g003
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PPARa Agonists Suppress Nicotine-induced sIPSCs in
Layer II–III Pyramidal Neurons in the Mouse and Rat
Frontal Cortex
Nicotine-induced seizures, as well as those spontaneously
occurring in transgenic mice carrying the NFLE mutations, might
be primarily generated within FCx circuits [12,29]. Since
excitatory transmission on FCx pyramidal neurons is not affected
by NFLE mutations or by nicotine [12], we carried out whole-cell
recordings of spontaneous inhibitory postsynaptic currents
(sIPSCs) from layer II/III pyramidal cells of mouse and rat
coronal slices.
Under voltage-clamp mode (Vholding = 0 mV to isolate sIPSCs
[12]), nicotine (5 mM, 30 s) significantly increased both frequency
and amplitude of sIPSCs in mouse pyramidal cells. sISPC
frequency was enhanced to 133.262.9% of baseline (P,0.0001,
n = 23, paired t-test), the amplitude to 116.567.5% of baseline
(P,0.05, n = 23, paired t-test) (Fig. 4, Table 1). In marked
contrast, pretreatment with the PPARa agonists WY (1 mM,
5 min) and fenofibrate (10 mM, 5 min) dramatically blunted the
effect of nicotine on sIPSCs. During nicotine application in the
presence of WY, sIPSC frequency was 91.8610.2% of baseline
and amplitude was 91.864.7% of control values (for both
parameters, P.0.05 vs. baseline, n = 7, paired t-test) (Fig. 4A,
Table 1). Consistently, the structurally different PPARa agonist
fenofibrate also suppressed nicotine-induced increase of sIPSC
frequency and amplitude (for both parameters, P.0.05 vs.
baseline, n= 6, paired t-test) (Fig. 4B, Table 1).
The effects of both PPARa agonists were blocked by the
synthetic PPARa antagonist MK. In the presence of MK (0.3 mM,
5 min) and either PPARa agonist, nicotine effects on sIPSCs
frequency and amplitude were fully restored. Hence, in slices
perfused with WY+MK or fenofibrate+MK, nicotine induced an
increase in sIPSC frequency to 141.7619.3% and to
172.5620.9% of baseline, respectively (P.0.05vs. nicotine alone,
n = 6–7, paired t-test; Table 1, Fig. 4A,B). Table 1 shows that
sIPSC amplitude in the presence of nicotine alone was not
significantly different from the amplitude in the presence of
nicotine+WY+MK or nicotine+fenofibrate+MK(P.0.05, n= 6,
paired t-test).
To assess whether suppression of nicotine effects by acute
PPARa agonists was species-specific we replicated the experiments
described above in Sprague Dawley rats. The results (Supporting
Results S1) confirmed that both WY and fenofibrate abolished
nicotine-induced effects in both species (Table 1; Figure S1).
Experiments with mice chronically fed with fenofibrate (0.2%
w/w for 14 days) confirmed that this drug abolishes nicotine-
induced increases in sIPSC frequency in FCx pyramidal neurons.
Hence, nicotine-induced increase in sIPCS frequency was
132.264.6% of baseline (n = 6) in CTRL mice vs. 99.765.6%
of baseline (n = 6) in FBR mice (P,0.05, Student’s t-test) (Fig. 4C).
Consistent with behavioral experiments, MK was unable to revert
the effect of fenofibrate, since in FBR mice MK did not restore the
effects of nicotine (sIPSC frequency in control animals was
187.5620.9% vs. 80.7617.6% in FBR mice).
The PPARa Agonist Enhances Phosphorylation of the b2
Subunit of nAChRs
Consistent with our previous reports [13,14], these findings led
us to hypothesize that PPARa might regulate the balance between
phosphorylated and dephosphorylated b2*nAChRs. To test this
hypothesis, we analyzed phosphorylation of b2 subunits with
Western blot after in vivo exposure to the synthetic PPARa agonist
WY. Rats were administered WY (40 mg/kg, i.p.) and after
15 min, brain were rapidly removed and the FCx were dissected.
As expected, in FCx total homogenates an increased immunore-
activity for phosphorylated b2 subunits was observed in WY-
treated animals (125.067.9% of controls, n = 7, p,0.01, Student’s
t-test) (Fig. 5).
Discussion
Our study shows that acute and chronic PPARa agonists,
including the clinically available fenofibrate, reduce nicotine-
induced behavioral and EEG seizure expression and abolish
nicotine-induced enhancement of sIPSCs in FCx pyramidal
neurons.
We presume, based on the present results and previous
extensive work by our group, that the mechanism whereby
PPARa exerts these effects involves phosphorylation of specific
nAChR subunits [13,14,22,23]. Indeed, nAChR channel proper-
ties depend on its tyrosine phosphorylation status, being the result
of a balance between tyrosine kinases and phosphatases [32],
which negatively or positively modulates nAChR-mediated
currents, respectively, and controls the number of functional
surface receptors [33].
We specifically measured the ratio of phosphorylated/dephos-
phorylated b2 subunits, which is increased in the FCx by acute
PPARa ligand treatment, but it is difficult to quantify this effect in
subunit combinations less abundantly expressed in the CNS.
Therefore, we cannot exclude that subunits other than the b2
might also be targeted by PPARa. However, it must be pointed
out that b2*nAChRs play a major role, yet not exclusive, in
Table 1. Table showing frequency and amplitude of spontaneous IPSCs recorded from mice and rat pyramidal neurons in layers II/
III of the frontal cortex.
Baseline Nicotine WY +Nicotine FBR +Nicotine WY+MK+Nicotine FBR+MK+Nicotine
C57BL/6J mice
Frequency, Hz 46.261.0 61.261.1*** 35.166.6 40.061.6 68.7612.2* 79.7616.7*
Amplitude, pA 17.860.8 19.860.8* 18.362.7 18.161.6 21.561.9* 20.361.5*
Rats
Frequency, Hz 15.363.2 22.264.7*** 15.8611 11.560.6 22.565.7** 22.567.7*
Amplitude, pA 16.460.7 21.361.5*** 13.460.8 14.061.3 25.165.4* 22.861.9*
Nicotine (5 mM) significantly increases both frequency and amplitude of sIPSC (*P,0.05, 01, ***P,0.001 vs baseline, paired t-test). Both WY14643 (WY 1 mM) and
fenofibrate (FBR, 10 mM) suppressed nicotine’s effects on sIPSCs frequency and amplitude. The PPARa antagonist MK886 restored nicotine’s effects on sIPSC frequency
(*P,0.05, **P,0.01 vs baseline, paired t-test).
doi:10.1371/journal.pone.0064541.t001
PPAR-Alpha Agonists as Novel Antiepileptics
PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e64541
nicotine-induced seizures [10,34]. In fact, the a4b2 subunit
combination is the most abundantly expressed in the whole brain
and particularly in regions relevant to ictogenesis, such as thalamo-
cortical circuits and FCx (see [12] and references therein).
Furthermore, it was shown by Klaassen et al. [12] that nicotine-
induced sIPSC in layer II/III of the FCx are mediated by a4b2
nAChRs, as they are insensitive to the a7-selective blocker
methyllycaconitine but fully blocked by the a4b2-selective
antagonist dihydro-b-erythroidine. However, it must be pointed
out that other nAChR subunits are implicated in nicotine-evoked
seizures. In particular, their severity is reduced in mice lacking a3,
a5, and b4 [35,36], but not a7 [24]. The role of a7, however, is
still controversial, since pharmacological experiments with selec-
Figure 4. The PPARa agonists WY14643 and fenofibrate
suppress nicotine-induced increase of spontaneous inhibitory
postsynaptic currents (sIPSC) in frontal cortex (FCx) pyramidal
neurons. The graphs illustrate that in mouse FCx slices, nicotine (5 mM
perfused at arrows for 30 s) increases sIPSCs frequency in layer II/III
pyramidal neurons. Acutely, the PPARa agonists WY14643 (1 mM, WY)
(A), and fenofibrate (10 mM) (B) fully suppressed nicotine-induced
increase in sIPSC frequency. Similarly, chronic fenofibrate (0.2% w/w for
14 days in food) fully suppressed nicotine-induced increase in sIPSC
frequency (C). The gray box represents the time of PPARa agonist (+/2
antagonist) perfusion. The PPARa antagonist MK886 (0.3 mM) (open
symbols) blocked the effects of acute WY (A) and fenofibrate (B), but
not the one of chronic fenofibrate (C), and restored nicotine-induced
increase in sIPSCs. Representative recordings of the effect of nicotine,
and of PPARa agonists and antagonist, on spontaneous IPSCs from
pyramidal cells at Vh = 0 mV are depicted on the upper part of panels A
and B. Symbols represent the average6S.E.M.
doi:10.1371/journal.pone.0064541.g004
Figure 5. The PPARa agonist WY14643 enhances phosphory-
lation of b2 subunits of the nicotinic acetylcholine receptors.
Graph and representative immunoblots showing that the PPARa
agonist WY (40 mg/kg, i.p.) caused an increase in b2-subunit
phosphorylation (*P,0.05) in rat frontal cortex homogenates. Tissue
lysates were subjected to immunoprecipitation (IP) with anti-b2 subunit
antibody and were immunoblotted (IB) with anti-phosphotyrosine (PY)
antibody. The blots were stripped and reprobed with anti-b2 subunit
antibody to normalize for protein loading.
doi:10.1371/journal.pone.0064541.g005
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tive a7 agonists and antagonists yielded contradictory results
[10,34].
Irrespectively of the subunits involved other than b2, the
PPARa agonists reduced both the severity of nicotine-induced
effects and the number of animals undergoing severe symptoms.
These behavioral effects were paralleled by a significant decrease
in the number of mice that showed bursts of spike-wave
discharges. The pharmacological specificity was confirmed by
the finding that pre-treatment with the PPARa antagonist
prevented the protection exerted by the agonist, with the exception
of chronic fenofibrate treatments. The latter finding might be
explained with the finding that PPARa activation induces fatty
acid metabolism [31] and NAE biosynthesis with increased
production of OEA. Notably, OEA would further sustain PPARa
activation by triggering a feed-forward mechanism difficult to be
antagonized by a single administration of the PPARa antagonist
MK. A second possible explanation is that changes induced by this
treatment regimen, possibly on function, number and phosphor-
ylation status of nAChRs, are not promptly reversed by an acute
treatment with the PPARa antagonist. Indeed, a reversal of
fenofibrate-induced protection is observed following a 14-days
washout of the drug, achieved by replacing fenofibrate-containing
food pellets with control food.
The present data, while confirming the relationship between
nAChRs and epileptogenesis, give support to the role played by
nuclear receptors PPARa in the modulation of nAChR function in
the CNS. Hence, in our previous studies, we demonstrated that
both endogenous and synthetic PPARa agonists suppressed
nicotine-induced electrophysiological effects on dopamine neurons
and prevented behavioral effects of nicotine predictive of its
addicting properties by regulating b2* nAChRs specifically
[13,14,15,16]. Here we extend those results to the seizure-inducing
action of nicotine.
Nuclear and cytoplasmic immunostaining for PPARa is present
in neurons distributed in all layers of the FCx [20,21], whereas
cholinergic afferents, arising principally from the basal forebrain,
innervate neurons in all layers of the rodent FCx [37]. Several
subtypes of GABA cortical interneurons express functional a4b2*
nAChRs [38,39] and have been involved in nicotine-induced
seizures [10,12,34,38] since they innervate adjacent pyramidal
cells. Consistently, we show that nicotine induced an increase in
the frequency of GABAA-mediated sIPSCs, possibly by depolar-
izing presynaptic GABAergic terminals impinging on pyramidal
neurons. According to behavioral observations, these effects were
suppressed by PPARa agonists, suggesting that PPARa regulate
the functions of nAChRs in cortical interneurons, similarly to
dopamine neurons.
Notably, the relevance of our results might extend beyond
nicotine-induced seizures or NFLE, since chronic fenofibrate was
effective in rats as anticonvulsant in pentylentetrazole-induced
seizures and on latencies to the onset of status epilepticus induced
by lithium–pilocarpine [30]. Additionally, recent studies demon-
strated that the antiepileptic drugs carbamazepine and lamotri-
gine, which are employed effectively also in NFLE patients,
negatively modulate the activity of a4b2 nAChRs [40,41]. This
effect might contribute to their mechanisms of action since these
receptors control neuronal excitability and both glutamate and
GABA release in the hippocampus and the thalamo-cortical
system [42,43,44,45,46].
In conclusion, we provided evidence that PPARa within the
CNS might be a key regulator of neuronal activity by the
modulation of functional properties of nAChRs. These effects
might be therapeutically exploited not only when nicotine
addiction is concerned [15], but also for idiopathic or genetically
determined forms of epilepsy where nAChRs play a major role.
Supporting Information
Figure S1 The PPARa agonists WY14643 and fenofibrate
suppress nicotine-induced increase of spontaneous inhibitory
postsynaptic currents (sIPSC) in rat frontal cortex (FCx) pyramidal
neurons. The graphs illustrate that in rat FCx slices, nicotine
(5 mM perfused at arrows for 30 s) increases sIPSCs frequency in
layer II/III pyramidal neurons. The PPARa agonists WY14643
(1 mM, WY) (A) and fenofibrate (10 mM) (B) (n = 6–7; closed
symbols) fully suppressed nicotine-induced increase in sIPSC
frequency. The gray box represents the time of PPARa agonist (+/
2 antagonist) perfusion. The PPARa antagonist MK886 (0.3 mM)
(open symbols) blocked the effects of WY (A) and fenofibrate (B)
(n = 6) and restored nicotine-induced increase in sIPSCs. Symbols
represent the mean6SEM.
(TIF)
Supporting Results S1 PPAR-a agonists suppress nicotine-
induced sIPSCs in layer II-III pyramidal neurons in the rat frontal
cortex.
(DOCX)
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